Approved non-peptide medicines

Defined small-molecule medicines that appeared in the source peptide catalog but must be classified and read as non-peptides.

This area keeps a critical identity distinction visible: inclusion in an external peptide catalog does not make a compound a peptide.

Tadalafil is a defined non-peptide small-molecule PDE5 inhibitor with product- and jurisdiction-specific approvals for erectile dysfunction, BPH symptoms and pulmonary arterial hypertension. Approval applies to authorised products and specific indications; it is not evidence for general libido, testosterone, weight-loss or vascular-health claims.

Approval does not remove interaction risk

Tadalafil is contraindicated with organic nitrates and with guanylate-cyclase stimulators such as riociguat. Product, indication, cardiovascular status and other medicines require clinical review.

1 peptides studied in this area

Tadalafil

Cialis

Tadalafil is a prescription PDE5 inhibitor—not a peptide—with regulator-approved uses for erectile dysfunction, benign prostatic hyperplasia and, under separate products, pulmonary arterial hypertension. Its long half-life and established efficacy sit beside important cardiovascular interactions, especially an absolute contraindication with nitrates or riociguat.

Reproductive & HormonalPrescription medicine with product- and jurisdiction-specific approvals